Induction of tolerance for islet transplantation for type 1 diabetes

Current Diabetes Reports

Volumn 3, Issue 4, 2003, Pages 329-335

  Seung, Edward ^b   Mordes, John P ^b   Greiner, Dale L ^b   Rossini, Aldo A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BUSULFAN; CD4 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD45 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; TACROLIMUS; MONOCLONAL ANTIBODY;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CHIMERA; CLINICAL PROTOCOL; DONOR; DRUG RECEPTOR BINDING; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH HAZARD; HUMAN; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; REVIEW; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME; VIRUS INFECTION; ANIMAL; BLOOD TRANSFUSION; DRUG EFFECT; HISTOCOMPATIBILITY; IMMUNOLOGY; METHODOLOGY; RECURRENT DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BLOOD TRANSFUSION; CD40 LIGAND; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; RECURRENCE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 0141671764     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0026-9     Document Type: Review

References (50)

1. Sorli CH, Greiner DL, Mordes JP, Rossini AA: Stem cell transplantation for treatment of autoimmune diseases. Graft 1998, 1:71-81.
2. Domenick MA, Ildstad ST: Impact of bone marrow transplantation on type I diabetes. World J Surg 2001, 25:474-480.
3. Rossini AA, Greiner DL, Mordes JP: Induction of immunological tolerance for transplantation. Physiol Rev 1999, 79:99-141.
4. Kelly WD, Lillehei RC, Merkel FK, et al.: Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967, 61:827-837.
5. Squifflet JP: New developments in pancreas and islet transplantation. Transplant Proc 2001, 33:3492-3493.
6. Sutherland DER, Gruessner RWG, Gruessner AC: Pancreas transplantation for treatment of diabetes mellitus. World J Surg 2001, 25:487-496.
7. White SA, James RF, Swift SM, et al.: Human islet cell transplantation - future prospects. Diabet Med 2001, 18:78-103.
8. Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230-238.
9. Ryan EA, Lakey JRT, Paty BW, et al.: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148-2157.
10. Laederach-Hofmann K, Bunzel B: Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry 2000, 22:412-424.
11. Soulillou JP, Giral M: Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001, 72:S89-S93.
12. Shihab F: Metabolic complications. In Primer on Transplantation. Edited by Norman D, Turka L. Mt. Laurel, NJ: American Society of Transplantation; 2001:247-256.
13. Starzl TE, Demetris AJ, Murase N, et al.: The lost chord: microchimerism and allograft survival. Immunol Today 1996, 17:577-584.
14. Armstrong HE, Bolton EM, McMillan I, et al.: Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med 1987, 165:891-907.
15. Jenkins MK, Schwartz RH: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987, 165:302-319.
16. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
17. Parker DC, Greiner DL, Phillips NE, et al.: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 1995, 92:9560-9564.
18. Markees TG, Phillips NE, Gordon EJ, et al.: Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4+ T cells, interferon-gamma, and CTLA4. J Clin Invest 1998, 101:2446-2455.
19. Li Y, Li XC, Zheng XX, et al.: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999, 5:1298-1302.
20. Wells AD, Li XC, Li Y, et al.: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999, 5:1303-1307.
21. Trambley J, Bingaman AW, Lin A, et al.: Asialo GM1+ CD8+ T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999, 104:1715-1722.
22. Iwakoshi NN, Mordes JP, Markees TG, et al.: Treatment of allograft recipients with donor specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000, 164:512-521.
23. Iwakoshi NN, Markees TG, Turgeon NA, et al.: Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol 2001, 167:6623-6630.
24. Taylor PA, Noelle RJ, Blazar BR: CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001, 193:1311-1317.
25. Hara M, Kingsley CI, Niimi M, et al.: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001, 166:3789-3796.
26. Graca L, Thompson S, Lin CY, et al.: Both CD4+CD25+ and CD4+CD25- regulatory cells mediate dominant transplantation tolerance. J Immunol 2002, 168:5558-5565.
27. Sakaguchi S: Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
28. Welsh RM, Markees TG, Woda BA, et al.: Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000, 74:2210-2218.
29. Turgeon NA, Iwakoshi NN, Phillips NE, et al.: Viral infection abrogates CD8+ T-cell deletion induced by costimulation blockade. J Surg Res 2000, 93:63-69.
30. Sykes M: Mixed chimerism and transplant tolerance. Immunity 2001, 14:417-424.
31. Locatelli F, Rondelli D, Burgio GR: Tolerance and hematopoietic stem cell transplantation 50 years after Burnet's theory. Exp Hematol 2000, 28:479-489.
32. Anderlini P, Giralt S, Andersson B, et al.: Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000, 26:615-620.
33. Wekerle T, Kurtz J, Sayegh MH, et al.: Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001, 166:2311-2316.
34. Wekerle T, Sayegh MH, Hill J, et al.: Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998, 187:2037-2044.
35. Adams AB, Durham MM, Kean L, MA et al.: Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001, 167:1103-1111.
36. Taylor PA, Lees CJ, Waldmann H, et al.: Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001, 98:467-474.
37. Durham MM, Bingaman AW, Adams AB, et al.: Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000, 165:1-4.
38. Wekerle T, Kurtz J, Ito H, et al.: Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000, 6:464-469.
39. Forman D, Welsh RM, Markees TG, et al.: Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J Immunol 2002, 168:6047-6056.
40. Williams MA, Tan JT, Adams AB, et al.: Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol 2001, 167:4987-4995.
41. Williams MA, Onami TM, Adams AB, et al.: Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002, 169:5387-5391.
42. Rossini AA, Mordes JP, Greiner DL, Stoff JS: Islet cell transplantation tolerance. Transplantation 2001, 72:S43-S46.
43. Sutherland DE, Sibley R, Xu XZ, et al.: Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians 1984, 97:80-87.
44. Markees TG, Serreze DV, Phillips NE, et al.: NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999, 48:967-974.
45. Molano RD, Berney T, Pileggi A, et al.: Prolonged survival of allogeneic islet grafts in NOD mice treated with a combination of anti-CD45RB and anti-CD154 antibodies. Transplant Proc 2001, 33:248-249.
46. Kreuwel HT, Biggs JA, Pilip IM, et al.: Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice. J Immunol 2001, 167:1112-1117.
47. Pearson T, Markees TG, Wicker LS, et al.: NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes 2003, 52:321-326.
48. Beilhack GF, Scheffold YC, Weissman IL, et al.: Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes 2003, 52:59-68.
49. Li H, Kaufman CL, Ildstad ST: Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery 1995, 118:192-198.
50. Seung E, Iwakoshi N, Woda BA, et al.: Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000, 95:2175-2182.